Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04950426
Other study ID # 2021-000312-36
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 13, 2021
Est. completion date August 12, 2024

Study information

Verified date August 2023
Source Centre Hospitalier Henri Laborit
Contact Nematollah JAAFARI, Professor
Phone 0033 5 16 52 61 18
Email namatollah.jaafari@ch-poitiers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to demonstrate a significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation blockade. Patients receive a treatment with propranolol associated with reconsolidation blockade of traumatic story once a week during 6 weeks, with evaluation at inclusion and at 3 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date August 12, 2024
Est. primary completion date August 12, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult over 18 years old - Diagnosis of fibromyalgia syndrome according to ACR 2016 criteria - PCL-5 > 44 suggesting the presence of a comorbid post-traumatic stress disorder - Meet the DSM-5 criteria for post-traumatic stress disorder secondary to exposure to a traumatic event according to DSM-5 criteria, both unique or repeated and regardless of the date or location of the traumatic event. - Pain relief treatment and/or psychotropic treatment stabilized for a period greater than or equal to two months. - Signature of a consent form - Patient able to understand and read french Exclusion Criteria: - Psychotic disorders - Unstable bipolar disorder - Patients with a systolic blood pressure < 100 mmHg or heart rate < 55 as established during the initial visit - Significant anormal ECG - Medical contraindication to taking propranolol - Adverse reactions or previous intolerances to a beta blocker - Current intake of another beta blocker which can not be stopped during the protocol, regardeless the galenic. - Current intake of a drug with potential contraindication with the propranolol, according to the summary of product characteristics of the propranolol. - Patient under legal protection, under guardianship or under curatorship - Patient having suffered a head trauma for less than a year or with clinical symptoms and neurological sequelae - Known severe suicide risk (MINI-S and medical exam) - Current opioid addiction or alcohol dependence - Patients treated for less than 2 months with antidepressants or painkillers - Patients unafiliated to a social health care - Woman who is pregnant or breast-feeding or whithout efficient contraception

Study Design


Intervention

Drug:
Propranolol
One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.

Locations

Country Name City State
France Centre Hospitalier Henri Laborit Poitiers
France Centre Hospitalier Nord-Deux-Sèvres Thouars

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Henri Laborit

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation therapy. Modification in quality of life in patients with fibromyalgia syndrome measured by the Fibromyalgia Impact Measurement Questionnaire (FIQ).
FIQ minimal value:0 (minimum impact) FIQ maximal value: 100 (maximal impact)
3 months
See also
  Status Clinical Trial Phase
Completed NCT03384706 - A Comparison of CPT Versus ART Versus WL N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03129204 - Sensation Awareness Focused Training for Spouses N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT05113277 - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT00644423 - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD) N/A
Completed NCT02989987 - NET for SGBV Survivors in Eastern DR Congo N/A
Completed NCT02320799 - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya N/A
Recruiting NCT02293291 - Thermal Clinic Treatment in Gulf War Illness Phase 1/Phase 2
Completed NCT02242136 - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants N/A
Completed NCT02720497 - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD N/A
Completed NCT01911585 - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01693978 - Contingency Outcomes in Prolonged Exposure N/A
Completed NCT01469754 - Longitudinal Survey Analysis in Lymphoma Survivors N/A
Completed NCT02362477 - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD Phase 3
Terminated NCT01239173 - Emotional Memory Reactivation in Posttraumatic Stress Disorder Phase 3